m-PEG10-COOH is a hydrophilic PEG-based ADC linker intermediate featuring a 10-unit PEG spacer and carboxyl terminal. It enhances antibody solubility, improves conjugation efficiency, and provides stability for controlled drug release in antibody-drug conjugate development and targeted cancer therapy.
Structure of 2409969-94-2
* For research and manufacturing use only. We do not sell to patients.
Size | Price | Stock | Quantity |
---|---|---|---|
-- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
m-PEG10-COOH is a polyethylene glycol derivative used widely in the field of bioconjugation and drug delivery. Here are some key applications of m-PEG10-COOH:
Drug Delivery Systems: m-PEG10-COOH is utilized in the development of drug delivery systems due to its ability to enhance solubility and stability of therapeutic agents. By conjugating drugs with m-PEG10-COOH, researchers can improve pharmacokinetics, allowing for more controlled and prolonged release of the medication.
Protein Pegylation: m-PEG10-COOH is employed in the pegylation of proteins to improve their therapeutic potential. This process involves attaching the m-PEG10-COOH polymer to protein therapeutics, which can enhance their stability, reduce immunogenicity, and extend circulation time in the bloodstream. As a result, pegylated proteins are more effective in clinical applications, such as in the treatment of cancer or autoimmune diseases.
Diagnostic Imaging: In diagnostic imaging, m-PEG10-COOH can be used to modify imaging agents, improving their biocompatibility and circulation time. By attaching m-PEG10-COOH to contrast agents, it is possible to achieve better resolution and more accurate imaging of tissues and organs. This application is particularly valuable in enhancing the detection and monitoring of diseases such as cancer.
Nanoparticle Surface Modification: m-PEG10-COOH is used to modify the surface of nanoparticles in various biomedical applications. By coating nanoparticles with m-PEG10-COOH, researchers can improve their solubility, bioavailability, and biocompatibility, making them more effective for drug delivery or imaging purposes. This surface modification minimizes nonspecific interactions and immune recognition, optimizing the performance of nanoparticle-based therapies.
Catalog | Product Name | CAS | Inquiry |
---|---|---|---|
BADC-00889 | m-PEG8-COOH | 1093647-41-6 | |
BADC-01952 | m-PEG11-COOH | 2280998-74-3 | |
BADC-01145 | m-PEG4-COOH | 67319-28-2 |
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.